<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1369">
  <stage>Registered</stage>
  <submitdate>14/11/2006</submitdate>
  <approvaldate>14/11/2006</approvaldate>
  <nctid>NCT00399906</nctid>
  <trial_identification>
    <studytitle>A Study of BMS-582949 in Patients With Moderate to Severe Plaque Psoriasis</studytitle>
    <scientifictitle>A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Clinical Efficacy, Safety, and Pharmacokinetics of Three Different Doses of BMS-582949 Given Orally to Subjects With Moderate to Severe Plaque Psoriasis</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>IM119-013</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Psoriasis</healthcondition>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Dermatological conditions</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Other skin conditions</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - BMS-582949
Treatment: drugs - Placebo

Active Comparator: A1 - 10 mg

Active Comparator: A2 - 30 mg

Active Comparator: A3 - 100 mg

Placebo Comparator: P1 - 10 or 100 mg


Treatment: drugs: BMS-582949
Tablets, Oral, Once daily, 12 weeks

Treatment: drugs: Placebo
Tablets, Oral, Once daily, 12 weeks

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The primary endpoint is the proportion of subjects achieving an IGA score of clear or almost clear at Week 12</outcome>
      <timepoint>at Week 12</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of subjects achieving a PASI-50</outcome>
      <timepoint>at Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of subjects achieving a PASI-75</outcome>
      <timepoint>at Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of subjects achieving a PASI-90</outcome>
      <timepoint>at Week 12</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Males and Females (not nursing or not pregnant)

          -  18-75 years of age

          -  Diagnosis of moderate to severe psoriasis for at least six months at the time of
             screening

          -  Subjects will require wash-out of certain therapies for the treatment of psoriasis but
             will be allowed to continue on certain topical therapies</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria />
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/08/2007</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>99</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/04/2009</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,VIC</recruitmentstate>
    <hospital>Local Institution - Kogarah</hospital>
    <hospital>Local Institution - Greenslopes</hospital>
    <hospital>Local Institution - North Adelaide</hospital>
    <hospital>Local Institution - Carlton</hospital>
    <hospital>Local Institution - Malvern</hospital>
    <postcode>2217 - Kogarah</postcode>
    <postcode>4120 - Greenslopes</postcode>
    <postcode>5006 - North Adelaide</postcode>
    <postcode>3053 - Carlton</postcode>
    <postcode>3144 - Malvern</postcode>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Manitoba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Newfoundland and Labrador</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Nova Scotia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Aguascalientes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Distrito Federal</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Jalisco</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Nuevo Leon</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Bristol-Myers Squibb</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this clinical research study is to learn if BMS-582949 alone is an effective
      treatment for moderate to severe psoriasis. The safety of the drug and the effectiveness of
      each dose will also be studied.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00399906</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Bristol-Myers Squibb</name>
      <address>Bristol-Myers Squibb</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>